Hemogenyx Pharmaceuticals plc, the biopharmaceutical company developing innovative therapies for blood malignancies, and Kure.ai (Kure), a company in ultrafast CAR-T manufacturing technology, announce a strategic collaboration to advance the production of CAR-T cell therapies for acute myeloid leukemia (AML) and a subset of acute lymphoblastic leukemia (ALL).

This partnership aims to integrate Kure’s ultrafast manufacturing (UM) technology with Hemogenyx Pharmaceuticals’s proprietary CAR-T therapy, HG-CT-1 (formerly known as HEMO-CAR-T) to enable faster, more efficient production of CAR-T cells, significantly reducing manufacturing timelines while maintaining therapeutic potency.

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented, “One of the most significant challenges in CAR-T therapy is the time and cost associated with manufacturing. Our partnership with Kure.ai allows us to explore and integrate a cutting-edge ultrafast manufacturing process that has the potential to revolutionize CAR-T production. This collaboration is an important step toward accelerating patient access to life-saving therapies.“

Dr. David Wald, Founder of Kure.ai and Professor at Case Western Reserve University, added, “We are excited to partner with Hemogenyx to adapt our ultrafast manufacturing platform to their innovative CAR-T therapy. This collaboration not only advances next-generation CAR-T solutions but also demonstrates the real-world clinical utility of our technology in addressing urgent unmet medical needs.”